Scholarlink

Purpose <p>To ascertain the clinical effectiveness of iPRF (injectable platelet rich fibrin) for the treatment of oral submucous fibrosis in its early stage.</p> Methods and Materials <p>This study comp rised of 40 subjects who were diagnosed with oral submucous fibrosis (OSMF) based on the history and clinical presentation. Subjects who gave a history of gutkha or pan chewing habit and presented with clinically reduced mouth opening and burning sensation on mastication are considered for this study. All the subjects were divided randomly in two groups of 20 subjects each. Subjects in group A received 2&#xa0;ml injection iPRF intralesionally while subjects in group B received 2&#xa0;ml of combined dexamethasone, placentrix and hyaluronidase injection intralesionally for the management of OSMF. iPRF was prepared from the patient’s own blood using a double spin technique in the same sitting. Patients in both the groups received intralesional injection at the fibrosed tissue weekly at regular intervals for 6&#xa0;weeks. Maximum interincisal distance was measured to assess the improvement in the mouth opening. Resolution of the fibrous band and evanesce of vesicles formation if any was noted. Reduction in the burning sensation on mastication was assessed and quantified with a visual analogue scale.</p> Results <p>The results of this study showed an identical improvement of both the subjective signs and symptoms in all subjects. However, the administration of iPRF was clinically more effective than hyaluronidase, corticosteroid and placentrix combination in retarding the discomfort and burning sensation on mastication along with improving the mouth opening. In addition to this pain on administration of iPRF is less as compared to pain on administration of hyaluronidase, corticosteroid and placentrix combination. No unforeseen side effects or at the site of administration was noted.</p> Conclusion <p>Administration of iPRF is clinically effective in the treating oral submucous fibrosis. Intralesional injections with iPRF is clinically a viable option to the exisitng conventional and adjuvant modalities in the current literature in the medical management of OSMF. In addition to this, iPRF causes minimal or nil systemic side effects and minimal or no burning sensation on administration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of iPRF in the Treatment of Oral Submucous Fibrosis: A Prospective Clinical Study

  • 期刊论文

  • 发表日期：

    2025年9月11日

查看全文
  • Uday Kiran Uppada,
  • P. N. Ramaraj,
  • Rounak Dubey

摘要

Purpose

To ascertain the clinical effectiveness of iPRF (injectable platelet rich fibrin) for the treatment of oral submucous fibrosis in its early stage.

Methods and Materials

This study comp rised of 40 subjects who were diagnosed with oral submucous fibrosis (OSMF) based on the history and clinical presentation. Subjects who gave a history of gutkha or pan chewing habit and presented with clinically reduced mouth opening and burning sensation on mastication are considered for this study. All the subjects were divided randomly in two groups of 20 subjects each. Subjects in group A received 2 ml injection iPRF intralesionally while subjects in group B received 2 ml of combined dexamethasone, placentrix and hyaluronidase injection intralesionally for the management of OSMF. iPRF was prepared from the patient’s own blood using a double spin technique in the same sitting. Patients in both the groups received intralesional injection at the fibrosed tissue weekly at regular intervals for 6 weeks. Maximum interincisal distance was measured to assess the improvement in the mouth opening. Resolution of the fibrous band and evanesce of vesicles formation if any was noted. Reduction in the burning sensation on mastication was assessed and quantified with a visual analogue scale.

Results

The results of this study showed an identical improvement of both the subjective signs and symptoms in all subjects. However, the administration of iPRF was clinically more effective than hyaluronidase, corticosteroid and placentrix combination in retarding the discomfort and burning sensation on mastication along with improving the mouth opening. In addition to this pain on administration of iPRF is less as compared to pain on administration of hyaluronidase, corticosteroid and placentrix combination. No unforeseen side effects or at the site of administration was noted.

Conclusion

Administration of iPRF is clinically effective in the treating oral submucous fibrosis. Intralesional injections with iPRF is clinically a viable option to the exisitng conventional and adjuvant modalities in the current literature in the medical management of OSMF. In addition to this, iPRF causes minimal or nil systemic side effects and minimal or no burning sensation on administration.